Pharmaceutically acceptable compound, salt or solvate or a mixture thereof； pharmaceutical composition, packaged pharmaceutical composition； method for treating a patient, increasing cancer cell sensitivity to chemotherapy, reducing measurement errors and improving therapeutic compliance, inhibiting atp hydrolysis and b-cell activity, and determining the presence of btk
PETER A. BLOMGREN,KEVIN S. CURRIE,JEFFREY E. KROPF,SEUNG H. LEE,SCOTT A. MITCHELL,JIANJUN XU,AARON C. SCHMITT,ZHONGDONG ZHAO,PAVEL E. ZHICHKIN,DOUGLAS G. STAFFORD
申请号：
BRPI0817130
公开号：
BRPI0817130A2
申请日:
2008.09.19
申请国别(地区):
BR
年份:
2015
代理人:
摘要：
Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/ or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
